Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 67
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for ARWR

Stock Name	Arrowhead Pharmaceuticals Inc
Ticker	ARWR(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US04280A1007
LEI	549300O3CSB8T7OZ3D66

Show aggregate ARWR holdings

News associated with ARWR

7 Biotech Stocks Trading At 52-Week Highs - Can The Rally Continue?: (RTTNews) - Patience is a virtue - important in all aspects of life, and especially crucial when it comes to investing. As trading expert Steve Burns once said, "Much of our trading comes down to a battle between our patience and our impulses." - 2025-09-15 03:55:16
Mitsubishi UFJ Asset Management Co. Ltd. Has $184,000 Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 9.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,476 shares of the biotechnology company’s stock after purchasing an additional […] - 2025-08-15 05:44:58
XTX Topco Ltd Buys New Shares in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): XTX Topco Ltd bought a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) in the 1st quarter, Holdings Channel.com reports. The fund bought 10,421 shares of the biotechnology company’s stock, valued at approximately $133,000. Several other institutional investors and hedge funds have also recently bought and sold shares of ARWR. GAMMA […] - 2025-08-15 05:02:51
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Mutual of America Capital Management LLC: Mutual of America Capital Management LLC trimmed its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 72.0% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 18,363 shares of the biotechnology company’s stock after selling 47,305 shares during the period. Mutual of America Capital Management […] - 2025-08-14 05:23:02
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at B. Riley: B. Riley upgraded shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) to a strong-buy rating in a report issued on Monday,Zacks.com reports. B. Riley also issued estimates for Arrowhead Pharmaceuticals’ Q4 2025 earnings at $0.69 EPS, FY2025 earnings at $0.82 EPS, FY2026 earnings at ($3.16) EPS, FY2027 earnings at ($0.75) EPS, FY2028 earnings at ($2.09) […] - 2025-08-14 02:42:49
Bullish Two Hundred Day Moving Average Cross - ARWR: In trading on Tuesday, shares of Arrowhead Pharmaceuticals Inc (Symbol: ARWR) crossed above their 200 day moving average of $17.48, changing hands as high as $18.13 per share. Arrowhead Pharmaceuticals Inc shares are currently trading up about 3.6% on the day. The chart below - 2025-08-12 12:55:22
Universal Beteiligungs und Servicegesellschaft mbH Makes New $174,000 Investment in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 13,622 shares of the biotechnology company’s stock, valued at approximately $174,000. Several other institutional […] - 2025-08-06 04:31:05
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to Strong-Buy at TD Cowen: Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) was upgraded by analysts at TD Cowen to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports. ARWR has been the topic of several other reports. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report […] - 2025-07-30 02:20:43
Mutual of America Capital Management LLC Trims Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): Mutual of America Capital Management LLC decreased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 72.0% during the 1st quarter, Holdings Channel.com reports. The firm owned 18,363 shares of the biotechnology company’s stock after selling 47,305 shares during the period. Mutual of America Capital Management LLC’s holdings in Arrowhead Pharmaceuticals […] - 2025-07-24 04:36:58
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Position Lowered by Bank of New York Mellon Corp: Bank of New York Mellon Corp lessened its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 6.5% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 776,039 shares of the biotechnology company’s stock after selling 54,019 shares during the period. Bank of New York […] - 2025-07-22 06:34:43
Bullish Two Hundred Day Moving Average Cross - ARWR: In trading on Wednesday, shares of Arrowhead Pharmaceuticals Inc (Symbol: ARWR) crossed above their 200 day moving average of $17.82, changing hands as high as $18.37 per share. Arrowhead Pharmaceuticals Inc shares are currently trading up about 3.2% on the day. The chart belo - 2025-07-09 12:39:36
Oregon Public Employees Retirement Fund Boosts Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): Oregon Public Employees Retirement Fund lifted its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 14.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 28,884 shares of the biotechnology company’s stock after buying an additional 3,546 shares during the quarter. Oregon Public […] - 2025-07-09 05:34:54
New York State Teachers Retirement System Buys 9,593 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): New York State Teachers Retirement System lifted its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 6.9% in the first quarter, HoldingsChannel.com reports. The firm owned 148,376 shares of the biotechnology company’s stock after purchasing an additional 9,593 shares during the period. New York State Teachers Retirement System’s holdings in Arrowhead […] - 2025-07-09 04:56:25
How The Parts Add Up: VIOO Headed For $118: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-23 08:46:06
Assenagon Asset Management S.A. Has $289,000 Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): Assenagon Asset Management S.A. trimmed its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 57.2% during the first quarter, HoldingsChannel reports. The institutional investor owned 22,701 shares of the biotechnology company’s stock after selling 30,312 shares during the period. Assenagon Asset Management S.A.’s holdings in Arrowhead Pharmaceuticals were worth $289,000 at […] - 2025-06-20 04:52:52
Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Price Target at $43.71: Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year […] - 2025-06-13 02:55:10
California State Teachers Retirement System Lowers Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): California State Teachers Retirement System trimmed its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 1.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 105,154 shares of the biotechnology company’s stock after selling 1,139 shares during the quarter. California State Teachers Retirement System’s holdings in Arrowhead Pharmaceuticals were worth $1,977,000 at […] - 2025-06-08 05:49:07
Mackenzie Financial Corp Buys New Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): Mackenzie Financial Corp acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) during the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 7,299 shares of the biotechnology company’s stock, valued at approximately $137,000. Other large investors also recently modified their holdings of the company. Raymond James Financial Inc. bought a new […] - 2025-06-06 04:49:00
Squarepoint Ops LLC Has $1.62 Million Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): Squarepoint Ops LLC reduced its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 55.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 86,044 shares of the biotechnology company’s stock after selling 107,750 shares during the quarter. Squarepoint Ops […] - 2025-05-30 06:08:58
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Tidal Investments LLC: Tidal Investments LLC lowered its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 4.8% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 21,249 shares of the biotechnology company’s stock after selling 1,062 shares during the period. Tidal Investments LLC’s holdings in Arrowhead Pharmaceuticals were […] - 2025-05-30 05:25:01
Millennium Management LLC Acquires 268,946 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): Millennium Management LLC lifted its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 41.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 914,550 shares of the biotechnology company’s stock after acquiring an additional 268,946 shares during the period. Millennium […] - 2025-05-22 05:01:01
HC Wainwright Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR): Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $80.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 422.53% from the company’s current price. […] - 2025-05-22 02:58:43
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Raised to “Hold” at StockNews.com: Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Wednesday. Several other equities analysts have also recently commented on the stock. B. Riley restated a “buy” rating and set a $38.00 price target (down from $51.00) on […] - 2025-05-16 05:46:55
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Comerica Bank: Comerica Bank reduced its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 5.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,921 shares of the biotechnology company’s stock after selling 2,259 shares during the quarter. Comerica Bank’s holdings […] - 2025-05-15 05:08:52
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given Buy Rating at Chardan Capital: Chardan Capital reaffirmed their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a report published on Tuesday,Benzinga reports. The firm currently has a $60.00 price objective on the biotechnology company’s stock. Several other research firms have also recently commented on ARWR. B. Riley reissued a “buy” rating and set a $38.00 […] - 2025-05-14 04:58:52
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target Cut to $17.00 by Analysts at Citigroup: Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its target price reduced by Citigroup from $21.00 to $17.00 in a research report released on Tuesday morning,Benzinga reports. Citigroup currently has a neutral rating on the biotechnology company’s stock. Several other equities research analysts also recently commented on the company. B. Riley restated a “buy” rating and […] - 2025-05-14 04:58:48
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Up After Strong Earnings: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) gapped up prior to trading on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $13.97, but opened at $15.75. Arrowhead Pharmaceuticals shares last traded at $15.56, with a volume of 844,732 shares trading hands. The biotechnology company reported $2.75 […] - 2025-05-14 02:40:47
Northern Trust Corp Purchases 151,654 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): Northern Trust Corp raised its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 11.4% in the 4th quarter, Holdings Channel.com reports. The firm owned 1,484,419 shares of the biotechnology company’s stock after buying an additional 151,654 shares during the period. Northern Trust Corp’s holdings in Arrowhead Pharmaceuticals were worth $27,907,000 at the end […] - 2025-05-12 05:36:56
Voya Investment Management LLC Sells 246,573 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): Voya Investment Management LLC trimmed its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 82.1% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 53,793 shares of the biotechnology company’s stock after selling 246,573 shares during the period. Voya Investment Management LLC’s holdings in Arrowhead Pharmaceuticals were worth $1,011,000 as of its […] - 2025-05-07 05:57:00
Bank of Montreal Can Boosts Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): Bank of Montreal Can grew its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 13.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,018 shares of the biotechnology company’s stock after purchasing an additional 1,759 shares […] - 2025-04-25 04:36:52

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) ARWR holdings

Date	Number of ARWR Shares Held	Base Market Value of ARWR Shares	Local Market Value of ARWR Shares	Change in ARWR Shares Held	Change in ARWR Base Value	Current Price per ARWR Share Held	Previous Price per ARWR Share Held
2025-12-03 (Wednesday)	97,033	USD 6,314,422	USD 6,314,422	0	USD 691,360	USD 65.075	USD 57.95
2025-12-02 (Tuesday)	97,033	USD 5,623,062	USD 5,623,062	3,450	USD 359,018	USD 57.95	USD 56.25
2025-12-01 (Monday)	93,583	USD 5,264,044	USD 5,264,044	0	USD 332,220	USD 56.25	USD 52.7
2025-11-28 (Friday)	93,583	USD 4,931,824	USD 4,931,824	230	USD -455,578	USD 52.7	USD 57.71
2025-11-27 (Thursday)	93,353	USD 5,387,402	USD 5,387,402	690	USD 39,820	USD 57.71	USD 57.71
2025-11-26 (Wednesday)	92,663	USD 5,347,582	USD 5,347,582	0	USD 1,011,880	USD 57.71	USD 46.79
2025-11-25 (Tuesday)	92,663	USD 4,335,702	USD 4,335,702	1,150	USD 285,337	USD 46.79	USD 44.26
2025-11-24 (Monday)	91,513	USD 4,050,365	USD 4,050,365	230	USD 357,968	USD 44.26	USD 40.45
2025-11-21 (Friday)	91,283	USD 3,692,397	USD 3,692,397	0	USD 215,428	USD 40.45	USD 38.09
2025-11-20 (Thursday)	91,283	USD 3,476,969	USD 3,476,969	-920	USD -116,182	USD 38.09	USD 38.97
2025-11-19 (Wednesday)	92,203	USD 3,593,151	USD 3,593,151	230	USD -128,996	USD 38.97	USD 40.47
2025-11-18 (Tuesday)	91,973	USD 3,722,147	USD 3,722,147	1,380	USD 84,838	USD 40.47	USD 40.15
2025-11-17 (Monday)	90,593	USD 3,637,309	USD 3,637,309	460	USD -81,579	USD 40.15	USD 41.26

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ARWR by Blackrock for IE00BDZVHG35

Show aggregate share trades of ARWR

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-12-02 BUY 3,450 59.270 55.750 56.102 USD 193,552 22.11
2025-11-28 BUY 230 56.670 52.080 52.539 USD 12,084 21.79
2025-11-27 BUY 690 57.710* 21.61
2025-11-25 BUY 1,150 46.920 43.720 44.040 USD 50,646 21.30
2025-11-24 BUY 230 44.850 40.430 40.872 USD 9,401 21.18
2025-11-20 SELL -920 39.920 37.060 37.346 USD -34,358 20.99 Loss of -15,043 on sale
2025-11-19 BUY 230 41.285 38.895 39.134 USD 9,001 20.90
2025-11-18 BUY 1,380 43.585 39.300 39.728 USD 54,825 20.80
2025-11-17 BUY 460 41.580 39.750 39.933 USD 18,369 20.70
2025-11-14 BUY 230 41.785 39.330 39.576 USD 9,102 20.59
2025-11-12 BUY 230 43.195 41.140 41.345 USD 9,509 20.37
2025-11-10 BUY 229 42.000 39.770 39.993 USD 9,158 20.15
2025-11-06 BUY 229 40.940 39.500 39.644 USD 9,078 19.94
2025-11-04 BUY 230 39.310 37.770 37.924 USD 8,723 19.73
2025-10-30 BUY 1,150 43.240 39.699 40.053 USD 46,061 19.37
2025-10-29 BUY 460 40.290 40.740 40.695 USD 18,720 19.25
2025-10-22 SELL -920 37.630 39.090 38.944 USD -35,828 18.70 Loss of -18,627 on sale
2025-10-20 BUY 460 38.470 38.560 38.551 USD 17,733 18.47
2025-10-17 BUY 1,149 36.810 39.360 39.105 USD 44,932 18.36
2025-10-15 BUY 1,832 38.190 38.630 38.586 USD 70,690 18.24
2025-10-03 BUY 1,596 36.120 36.240 36.228 USD 57,820 18.03
2025-10-02 BUY 228 34.600 35.650 35.545 USD 8,104 17.93
2025-09-30 BUY 456 34.490 34.610 34.598 USD 15,777 17.72
2025-09-26 BUY 456 32.800 32.860 32.854 USD 14,981 17.53
2025-09-25 BUY 456 31.660 33.130 32.983 USD 15,040 17.44
2025-09-18 BUY 240 31.510 31.620 31.609 USD 7,586 17.36
2025-09-17 BUY 723 29.130 30.400 30.273 USD 21,887 17.28
2025-07-17 SELL -482 18.850 19.045 19.026 USD -9,170 17.21 Loss of -873 on sale
2025-07-16 BUY 1,489 18.300 18.430 18.417 USD 27,423 17.21
2025-07-11 SELL -1,896 18.310 18.690 18.652 USD -35,364 17.19 Loss of -2,775 on sale
2025-07-02 BUY 13,035 16.900 16.980 16.972 USD 221,230 17.17
2025-06-25 BUY 474 15.660 16.115 16.069 USD 7,617 17.21
2025-06-20 BUY 6,994 15.320 15.921 15.861 USD 110,931 17.24
2025-06-11 BUY 426 16.740 17.490 17.415 USD 7,419 17.31
2025-06-10 BUY 428 16.970 17.300 17.267 USD 7,390 17.31
2025-06-04 SELL -214 16.740 17.080 17.046 USD -3,648 17.34 Profit of 62 on sale
2025-04-23 BUY 214 13.010 13.450 13.406 USD 2,869 18.15
2025-04-10 SELL -1,704 11.110 11.400 11.371 USD -19,376 18.79 Profit of 12,639 on sale
2025-04-08 SELL -214 9.990 10.970 10.872 USD -2,327 18.97 Profit of 1,733 on sale
2025-04-07 SELL -214 10.250 11.070 10.988 USD -2,351 19.07 Profit of 1,730 on sale
2025-04-04 SELL -1,070 10.680 11.960 11.832 USD -12,660 19.17 Profit of 7,851 on sale
2025-04-01 BUY 2,658 12.205 12.920 12.849 USD 34,151 19.33
2025-03-31 SELL -624 12.740 13.435 13.366 USD -8,340 19.41 Profit of 3,773 on sale
2025-03-21 BUY 3,503 14.800 15.220 15.178 USD 53,169 19.81
2025-03-14 SELL -3,152 15.360 15.624 15.598 USD -49,164 20.12 Profit of 14,257 on sale
2025-03-07 SELL -392 16.970 17.580 17.519 USD -6,867 20.46 Profit of 1,154 on sale
2025-03-04 SELL -196 17.110 17.480 17.443 USD -3,419 20.61 Profit of 621 on sale
2025-02-25 BUY 392 19.530 19.815 19.787 USD 7,756 20.76
2025-02-19 SELL -196 21.080 21.240 21.224 USD -4,160 20.80 Loss of -83 on sale
2025-02-13 BUY 588 19.110 19.210 19.200 USD 11,290 20.88
2025-02-12 BUY 196 18.570 18.610 18.606 USD 3,647 20.92
2025-02-11 BUY 780 18.890 19.800 19.709 USD 15,373 20.97
2024-12-30 SELL -6,769 18.610 19.030 18.988 USD -128,530 21.40 Profit of 16,308 on sale
2024-11-18 SELL -3,198 19.020 19.100 19.092 USD -61,056 20.39 Profit of 4,137 on sale
2024-11-08 SELL -214 21.890 21.920 21.917 USD -4,690 20.20 Loss of -368 on sale
2024-10-21 SELL -214 20.490 21.170 21.102 USD -4,516 0.00 Loss of -4,516 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-02	BUY	3,450	59.270	55.750	56.102	USD 193,552	22.11
2025-11-28	BUY	230	56.670	52.080	52.539	USD 12,084	21.79
2025-11-27	BUY	690			57.710*		21.61
2025-11-25	BUY	1,150	46.920	43.720	44.040	USD 50,646	21.30
2025-11-24	BUY	230	44.850	40.430	40.872	USD 9,401	21.18
2025-11-20	SELL	-920	39.920	37.060	37.346	USD -34,358	20.99 Loss of -15,043 on sale
2025-11-19	BUY	230	41.285	38.895	39.134	USD 9,001	20.90
2025-11-18	BUY	1,380	43.585	39.300	39.728	USD 54,825	20.80
2025-11-17	BUY	460	41.580	39.750	39.933	USD 18,369	20.70
2025-11-14	BUY	230	41.785	39.330	39.576	USD 9,102	20.59
2025-11-12	BUY	230	43.195	41.140	41.345	USD 9,509	20.37
2025-11-10	BUY	229	42.000	39.770	39.993	USD 9,158	20.15
2025-11-06	BUY	229	40.940	39.500	39.644	USD 9,078	19.94
2025-11-04	BUY	230	39.310	37.770	37.924	USD 8,723	19.73
2025-10-30	BUY	1,150	43.240	39.699	40.053	USD 46,061	19.37
2025-10-29	BUY	460	40.290	40.740	40.695	USD 18,720	19.25
2025-10-22	SELL	-920	37.630	39.090	38.944	USD -35,828	18.70 Loss of -18,627 on sale
2025-10-20	BUY	460	38.470	38.560	38.551	USD 17,733	18.47
2025-10-17	BUY	1,149	36.810	39.360	39.105	USD 44,932	18.36
2025-10-15	BUY	1,832	38.190	38.630	38.586	USD 70,690	18.24
2025-10-03	BUY	1,596	36.120	36.240	36.228	USD 57,820	18.03
2025-10-02	BUY	228	34.600	35.650	35.545	USD 8,104	17.93
2025-09-30	BUY	456	34.490	34.610	34.598	USD 15,777	17.72
2025-09-26	BUY	456	32.800	32.860	32.854	USD 14,981	17.53
2025-09-25	BUY	456	31.660	33.130	32.983	USD 15,040	17.44
2025-09-18	BUY	240	31.510	31.620	31.609	USD 7,586	17.36
2025-09-17	BUY	723	29.130	30.400	30.273	USD 21,887	17.28
2025-07-17	SELL	-482	18.850	19.045	19.026	USD -9,170	17.21 Loss of -873 on sale
2025-07-16	BUY	1,489	18.300	18.430	18.417	USD 27,423	17.21
2025-07-11	SELL	-1,896	18.310	18.690	18.652	USD -35,364	17.19 Loss of -2,775 on sale
2025-07-02	BUY	13,035	16.900	16.980	16.972	USD 221,230	17.17
2025-06-25	BUY	474	15.660	16.115	16.069	USD 7,617	17.21
2025-06-20	BUY	6,994	15.320	15.921	15.861	USD 110,931	17.24
2025-06-11	BUY	426	16.740	17.490	17.415	USD 7,419	17.31
2025-06-10	BUY	428	16.970	17.300	17.267	USD 7,390	17.31
2025-06-04	SELL	-214	16.740	17.080	17.046	USD -3,648	17.34 Profit of 62 on sale
2025-04-23	BUY	214	13.010	13.450	13.406	USD 2,869	18.15
2025-04-10	SELL	-1,704	11.110	11.400	11.371	USD -19,376	18.79 Profit of 12,639 on sale
2025-04-08	SELL	-214	9.990	10.970	10.872	USD -2,327	18.97 Profit of 1,733 on sale
2025-04-07	SELL	-214	10.250	11.070	10.988	USD -2,351	19.07 Profit of 1,730 on sale
2025-04-04	SELL	-1,070	10.680	11.960	11.832	USD -12,660	19.17 Profit of 7,851 on sale
2025-04-01	BUY	2,658	12.205	12.920	12.849	USD 34,151	19.33
2025-03-31	SELL	-624	12.740	13.435	13.366	USD -8,340	19.41 Profit of 3,773 on sale
2025-03-21	BUY	3,503	14.800	15.220	15.178	USD 53,169	19.81
2025-03-14	SELL	-3,152	15.360	15.624	15.598	USD -49,164	20.12 Profit of 14,257 on sale
2025-03-07	SELL	-392	16.970	17.580	17.519	USD -6,867	20.46 Profit of 1,154 on sale
2025-03-04	SELL	-196	17.110	17.480	17.443	USD -3,419	20.61 Profit of 621 on sale
2025-02-25	BUY	392	19.530	19.815	19.787	USD 7,756	20.76
2025-02-19	SELL	-196	21.080	21.240	21.224	USD -4,160	20.80 Loss of -83 on sale
2025-02-13	BUY	588	19.110	19.210	19.200	USD 11,290	20.88
2025-02-12	BUY	196	18.570	18.610	18.606	USD 3,647	20.92
2025-02-11	BUY	780	18.890	19.800	19.709	USD 15,373	20.97
2024-12-30	SELL	-6,769	18.610	19.030	18.988	USD -128,530	21.40 Profit of 16,308 on sale
2024-11-18	SELL	-3,198	19.020	19.100	19.092	USD -61,056	20.39 Profit of 4,137 on sale
2024-11-08	SELL	-214	21.890	21.920	21.917	USD -4,690	20.20 Loss of -368 on sale
2024-10-21	SELL	-214	20.490	21.170	21.102	USD -4,516	0.00 Loss of -4,516 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ARWR

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	376,407	0	674,979	55.8%
2025-09-18	524,054	0	960,097	54.6%
2025-09-17	296,152	32	760,755	38.9%
2025-09-16	300,051	0	670,150	44.8%
2025-09-15	427,642	266	1,049,258	40.8%
2025-09-12	668,159	0	1,301,349	51.3%
2025-09-11	670,369	0	1,229,353	54.5%
2025-09-10	529,944	6,375	1,121,514	47.3%
2025-09-09	454,584	0	871,626	52.2%
2025-09-08	476,666	858	1,027,436	46.4%
2025-09-05	686,687	210	1,180,731	58.2%
2025-09-04	742,951	4,969	1,545,175	48.1%
2025-09-03	1,333,950	1,813	2,542,566	52.5%
2025-09-02	1,629,551	341	3,050,134	53.4%
2025-08-29	440,043	88	939,594	46.8%
2025-08-28	600,944	667	1,089,854	55.1%
2025-08-27	476,742	0	1,080,158	44.1%
2025-08-26	255,096	6,673	497,972	51.2%
2025-08-25	325,407	0	737,032	44.2%
2025-08-22	390,846	0	1,019,888	38.3%
2025-08-21	512,903	0	960,943	53.4%
2025-08-20	491,191	0	810,629	60.6%
2025-08-19	285,275	103	713,720	40.0%
2025-08-18	453,719	5	992,734	45.7%
2025-08-15	649,082	300	2,430,373	26.7%
2025-08-14	709,646	1,225	1,999,536	35.5%
2025-08-13	522,775	2,995	993,887	52.6%
2025-08-12	323,869	0	582,559	55.6%
2025-08-11	529,705	0	829,914	63.8%
2025-08-08	493,638	0	1,028,510	48.0%
2025-08-07	425,190	7,755	631,002	67.4%
2025-08-06	518,065	52	684,201	75.7%
2025-08-05	259,725	26	425,967	61.0%
2025-08-04	256,316	0	388,359	66.0%
2025-08-01	392,309	83	526,391	74.5%
2025-07-31	246,862	0	395,659	62.4%
2025-07-30	417,967	775	558,891	74.8%
2025-07-29	354,962	311	535,847	66.2%
2025-07-28	391,556	5,215	548,954	71.3%
2025-07-25	511,612	0	601,832	85.0%
2025-07-24	809,703	472	1,100,539	73.6%
2025-07-23	1,142,651	1,877	1,501,510	76.1%
2025-07-22	543,615	37,241	944,114	57.6%
2025-07-21	1,927,857	40,089	3,233,118	59.6%
2025-07-18	599,891	1,370	939,779	63.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE